Jennifer A. Woyach, MD, Discusses Previous Results of the AO41202 Trial Examining Ibrutinib Regimens in CLL

Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.

During the 2021 American Society of Hematology Annual Meeting, Jennifer A. Woyach, MD, associate professor in the Division of Hematology at The Ohio State University, discussed previously reported results of the phase 3 AO41202 study (NCT01886872), which looked to treat patients over 65 years of age who had not received prior therapy with ibrutinib (Imbruvica) regimens or chemoimmunotherapy for chronic lymphocytic leukemia (CLL). Woyach discusses prior results in anticipation of updated data that will be presented at the meeting.

Transcript:

The AO41202 study is a National Clinical Trials Network [NCTN]-sponsored phase 3 trial led by the Alliance for Clinical Trials in Oncology. In this study, we looked at the optimal care of older patients with previously untreated CLL. This study is for patients who are age 65 or older who had not received prior CLL therapy. We randomized them 1:1:1 for treatment with bendamustine plus rituximab, or ibrutinib given alone or ibrutinib given in combination with rituximab. The primary results of the study showed that either regimen containing ibrutinib showed superior progression-free survival to bendamustine and rituximab, and there was no difference between the 2 ibrutinib containing regimens.

Reference

Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528. doi:10.1056/NEJMoa1812836

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
Related Content